{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-245484","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2026-05-28T21:06:28+00:00","discovered_at":"2026-05-28T21:08:00.315904+00:00","generated_at":"2026-05-28T21:15:21.054418+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director","bullets":["Zachary Roberts, M.D., Ph.D., currently EVP R&D and CMO, named President and CEO effective July 1, 2026.","Dr. Roberts receives $680k base salary, 60% target bonus, options for 476,190 shares, and 134,530 RSUs.","Outgoing CEO David Chang, M.D., Ph.D. will remain on the Board as a non-employee director after June 30, 2026.","Dr. Chang eligible for severance benefits under Allogene's Change in Control and Severance Benefit Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-245484","json":"https://secwatch.observer/filing/0001193125-26-245484.json","markdown":"https://secwatch.observer/filing/0001193125-26-245484.md","text":"https://secwatch.observer/filing/0001193125-26-245484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/d65280d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:15:21.054418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18865b97bf","claim":"Zachary Roberts was appointed as President and Chief Executive Officer at Allogene Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","confidence":0.95},{"claim_id":"1bad2c1b70","claim":"David Chang was appointed as non-employee director at Allogene Therapeutics, Inc..","evidence_excerpt":"Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","confidence":0.95},{"claim_id":"251b68b71b","claim":"David Chang resigned as President and Chief Executive Officer at Allogene Therapeutics, Inc..","evidence_excerpt":"Dr. Chang’s last day of service in these positions will be June 30, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","confidence":0.95},{"claim_id":"43fe04daa5","claim":"Zachary Roberts changed role as Chief Medical Officer (interim) at Allogene Therapeutics, Inc..","evidence_excerpt":"Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","confidence":0.8},{"claim_id":"d2e8883ed6","claim":"Zachary Roberts was appointed as Class I director at Allogene Therapeutics, Inc..","evidence_excerpt":"Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-251709","ticker":"CRVL","company_name":"CORVEL CORP","filed_at":"2026-06-01T21:05:42+00:00","headline":"CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251709","json":"https://secwatch.observer/filing/0001193125-26-251709.json","markdown":"https://secwatch.observer/filing/0001193125-26-251709.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/d24231d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0001671933-26-000063","ticker":"TTD","company_name":"Trade Desk, Inc.","filed_at":"2026-06-01T20:35:28+00:00","headline":"The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001671933-26-000063","json":"https://secwatch.observer/filing/0001671933-26-000063.json","markdown":"https://secwatch.observer/filing/0001671933-26-000063.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/ttd-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm"}},{"accession":"0000105770-26-000080","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","headline":"West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000080","json":"https://secwatch.observer/filing/0000105770-26-000080.json","markdown":"https://secwatch.observer/filing/0000105770-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/wst-20260531.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"}},{"accession":"0000060519-26-000024","ticker":"LPX","company_name":"LOUISIANA-PACIFIC CORP","filed_at":"2026-06-01T20:31:12+00:00","headline":"LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000060519-26-000024","json":"https://secwatch.observer/filing/0000060519-26-000024.json","markdown":"https://secwatch.observer/filing/0000060519-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/lpx-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm"}},{"accession":"0001193125-26-251522","ticker":"VRRM","company_name":"VERRA MOBILITY Corp","filed_at":"2026-06-01T20:29:13+00:00","headline":"Verra Mobility CEO David Roberts steps down amid cost realignment; interim CEO Keyser appointed","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251522","json":"https://secwatch.observer/filing/0001193125-26-251522.json","markdown":"https://secwatch.observer/filing/0001193125-26-251522.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682745/000119312526251522/0001193125-26-251522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682745/000119312526251522/d39754d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"On June 1, 2026, Verra Mobility Corporation (the “Company”) announced that the Board of Directors of the Company (the “Board”) approved the appointment of Jonathan Keyser as the Interim President and Chief Executive Officer of the Company, effective May 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1682745/000119312526251522/0001193125-26-251522-index.htm"}},{"accession":"0001193125-26-251467","ticker":"PENG","company_name":"Penguin Solutions, Inc.","filed_at":"2026-06-01T20:17:28+00:00","headline":"Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251467","json":"https://secwatch.observer/filing/0001193125-26-251467.json","markdown":"https://secwatch.observer/filing/0001193125-26-251467.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/d104493d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm"}},{"accession":"0002064307-26-000007","ticker":"LOGC","company_name":"ContextLogic Holdings Inc.","filed_at":"2026-06-01T20:15:17+00:00","headline":"ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002064307-26-000007","json":"https://secwatch.observer/filing/0002064307-26-000007.json","markdown":"https://secwatch.observer/filing/0002064307-26-000007.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/logc-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm","comparable_excerpt":"On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}